525 related articles for article (PubMed ID: 36820511)
1. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Ardebili A; Izanloo A; Rastegar M
Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
[TBL] [Abstract][Full Text] [Related]
2. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Scudeller L; Righi E; Chiamenti M; Bragantini D; Menchinelli G; Cattaneo P; Giske CG; Lodise T; Sanguinetti M; Piddock LJV; Franceschi F; Ellis S; Carrara E; Savoldi A; Tacconelli E
Int J Antimicrob Agents; 2021 May; 57(5):106344. PubMed ID: 33857539
[TBL] [Abstract][Full Text] [Related]
3. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
Lenhard JR; Thamlikitkul V; Silveira FP; Garonzik SM; Tao X; Forrest A; Soo Shin B; Kaye KS; Bulitta JB; Nation RL; Li J; Tsuji BT
J Antimicrob Chemother; 2017 May; 72(5):1415-1420. PubMed ID: 28333347
[TBL] [Abstract][Full Text] [Related]
4. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.
Quale J; Shah N; Kelly P; Babu E; Backer M; Rosas-Garcia G; Salamera J; George A; Bratu S; Landman D
Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342
[TBL] [Abstract][Full Text] [Related]
5. Multidrug-resistant Gram-negative infections: what are the treatment options?
Giamarellou H; Poulakou G
Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
[TBL] [Abstract][Full Text] [Related]
6. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.
Doymaz MZ; Karaaslan E
Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061
[No Abstract] [Full Text] [Related]
7. Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli.
Zhang Y; Zhao C; Wang Q; Wang X; Chen H; Li H; Zhang F; Wang H
J Antimicrob Chemother; 2020 Sep; 75(9):2609-2615. PubMed ID: 32591806
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae.
Clock SA; Tabibi S; Alba L; Kubin CJ; Whittier S; Saiman L
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):343-6. PubMed ID: 23601454
[TBL] [Abstract][Full Text] [Related]
9. The Anthelmintic Drug Niclosamide Synergizes with Colistin and Reverses Colistin Resistance in Gram-Negative Bacilli.
Domalaon R; De Silva PM; Kumar A; Zhanel GG; Schweizer F
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917988
[TBL] [Abstract][Full Text] [Related]
10. Colistin and polymyxin B in critical care.
Michalopoulos A; Falagas ME
Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
[TBL] [Abstract][Full Text] [Related]
11. Polymyxin Combinations Combat
Bulman ZP; Chen L; Walsh TJ; Satlin MJ; Qian Y; Bulitta JB; Peloquin CA; Holden PN; Nation RL; Li J; Kreiswirth BN; Tsuji BT
mBio; 2017 Jul; 8(4):. PubMed ID: 28743810
[TBL] [Abstract][Full Text] [Related]
12. Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration.
Papadopoulos A; Ribera A; Mavrogenis AF; Rodriguez-Pardo D; Bonnet E; Salles MJ; Dolores Del Toro M; Nguyen S; Blanco-García A; Skaliczki G; Soriano A; Benito N; Petersdorf S; Pasticci MB; Tattevin P; Tufan ZK; Chan M; O'Connell N; Pantazis N; Kyprianou A; Pigrau C; Megaloikonomos PD; Senneville E; Ariza J; Papagelopoulos PJ; Giannitsioti E;
Int J Antimicrob Agents; 2019 Mar; 53(3):294-301. PubMed ID: 30395988
[TBL] [Abstract][Full Text] [Related]
13. The use of polymyxins to treat carbapenem resistant infections in neonates and children.
Thomas R; Velaphi S; Ellis S; Walker AS; Standing JF; Heath P; Sharland M; Dona' D
Expert Opin Pharmacother; 2019 Mar; 20(4):415-422. PubMed ID: 30576264
[TBL] [Abstract][Full Text] [Related]
14. Clinical Use of Polymyxin B.
Rigatto MH; Falci DR; Zavascki AP
Adv Exp Med Biol; 2019; 1145():197-218. PubMed ID: 31364080
[TBL] [Abstract][Full Text] [Related]
15. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.
Karakonstantis S; Kritsotakis EI; Gikas A
Infection; 2020 Dec; 48(6):835-851. PubMed ID: 32875545
[TBL] [Abstract][Full Text] [Related]
16. Rational use of intravenous polymyxin B and colistin: A review.
Zakuan ZD; Suresh K
Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
[TBL] [Abstract][Full Text] [Related]
17. Polymyxins: To Combine or Not to Combine?
Perez F; El Chakhtoura NG; Yasmin M; Bonomo RA
Antibiotics (Basel); 2019 Apr; 8(2):. PubMed ID: 30974813
[TBL] [Abstract][Full Text] [Related]
18. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003
[TBL] [Abstract][Full Text] [Related]
19. Is it time to move away from polymyxins?: evidence and alternatives.
Soman R; Bakthavatchalam YD; Nadarajan A; Dwarakanathan HT; Venkatasubramanian R; Veeraraghavan B
Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):461-475. PubMed ID: 33009595
[TBL] [Abstract][Full Text] [Related]
20. Comparative metabolomics reveals key pathways associated with the synergistic activity of polymyxin B and rifampicin combination against multidrug-resistant Acinetobacter baumannii.
Zhao J; Han ML; Zhu Y; Lin YW; Wang YW; Lu J; Hu Y; Tony Zhou Q; Velkov T; Li J
Biochem Pharmacol; 2021 Feb; 184():114400. PubMed ID: 33387481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
